Autoimmune Diagnostics Market to reach USD 10.63 Billion by 2033 Driven by Rising Disease Burden and Innovation

Autoimmune Disease Diagnostics Market Overview
Due to the increasing prevalence of autoimmune diseases such as multiple sclerosis, lupus, and rheumatoid arthritis, the market for autoimmune disease diagnostics is expanding steadily. Key motivators include increased awareness, advancements in diagnostic technology, and enhanced healthcare infrastructure. For early and precise detection, methods including ELISA, immunofluorescence, and molecular diagnostics are essential. Due to significant investments in healthcare and research, North America leads the industry, followed by Europe. As healthcare knowledge and access continue to develop, emerging markets in the Asia-Pacific region are expected to expand rapidly. However, problems such as the absence of standardized testing and the high cost of diagnostics persist. The market's future is expected to be shaped by ongoing innovation and customized diagnostic techniques, which will improve patient outcomes and illness management.

According to Renub Research, Autoimmune Disease Diagnostics Market is anticipated to grow at a compound annual growth rate (CAGR) of 7.17% from 2025 to 2033, from US$ 5.70 billion in 2024 to US$ 10.63 billion in 2033.

Product
• Therapeutic & Monitoring Equipment
• Diagnostics Equipment
• Drugs

The market for autoimmune disease diagnostics is expected to grow due to the increasing prevalence of autoimmune illnesses. According to the 2020 Atlas of Multiple Sclerosis Report, there are presently over 2.8 million persons with multiple sclerosis globally, including over 1 million in the US. This contributes to the alarming statistics on autoimmune diseases globally. The rising prevalence of autoimmune diseases is a concern for European countries. According to the Multiple Sclerosis Trust, there will be 2.5 million cases of multiple sclerosis globally in 2020, with the highest frequency in Europe.
Multiple sclerosis is more common in women than in men. Psoriasis, one of the most common autoimmune diseases, is estimated to afflict 2% to 3% of the general population, whereas rheumatoid arthritis affects two million people. Programs for research, education, support, and activism have led to a greater awareness of autoimmune illnesses, which is a primary factor driving higher usage rates.

Key information covered in the report.
Base Year - 2024
Historical Period - 2020-2024
Market Forecast - 2025-2033
Market - US$ Billion

Request a free sample copy of the report: https://www.renub.com/autoimmune-disease-diagnostic-market-p.php

Market Trends for Autoimmune Disease Diagnosis: Developments in Diagnostic Technologies
To detect certain autoimmune disorders, including lupus, rheumatoid arthritis, and celiac disease, new biomarkers such as autoantibodies have been identified. More accurate categorization and early detection of autoimmune disorders can be achieved through the use of biomarkers. Due to advancements in proteomics and metabolomics, more customized diagnostics are making it possible to identify unique protein signatures or metabolic profiles connected to autoimmune illnesses. Additionally, the simultaneous assessment of multiple biomarkers, made possible by microarray technology, facilitates the diagnosis of complex autoimmune disorders involving numerous genetic or protein components. Furthermore, businesses are introducing innovative goods and technology, which is improving the outlook for the autoimmune disease diagnostic market.
For example, on March 25, 2024, AbbVie Inc. and Landos Biopharma, Inc. announced a definitive agreement under which AbbVie would acquire Landos, a biopharmaceutical company in the clinical stage specializing in the development of innovative oral therapies for patients with autoimmune diseases. NX-13, a first-in-class oral NLRX1 agonist with a bimodal mode of action (MOA), is Landos' primary research asset.

Types
• Systemic
• Localized

Indication
• Rheumatic Disease
• Diabetes
• Multiple Sclerosis
• Inflammatory Bowel Disease
• Others

In what ways do new biomarkers enhance the early identification of autoimmune diseases?
By improving diagnostic precision, reducing delays, and facilitating individualized treatments, emerging biomarkers are transforming the early diagnosis of autoimmune diseases. Long-standing issues, including vague symptoms, seronegative patients, and the overlap between autoimmune and other conditions, are addressed by these developments.
• New Protein Biomarkers and Autoantibodies
Newly discovered autoantibodies, like those that target IgLON5 and dipeptidyl-peptidase-like protein 6 (DPPX), broaden the diagnostic range for autoimmune encephalitis (AE), enabling medical professionals to distinguish AE from mimic conditions like neurodegenerative diseases and discover hitherto unknown subtypes. Similarly, even in individuals without conventional antibodies, Argonaute autoantibodies (AGO-Abs) serve as biomarkers for autoimmune neurologic diseases, enabling an earlier diagnosis of autoimmunity. Biomarkers, including TC4d, anti-RA33, and anti-CarP, enhance sensitivity, particularly in seronegative cases, and reduce diagnostic uncertainty for systemic diseases such as lupus and rheumatoid arthritis (RA).
• Biomarkers Based on Blood
Cerebrospinal fluid (CSF) analysis and other invasive techniques are being replaced with noninvasive blood testing. For instance, a B cell subset biomarker associated with Sjögren's syndrome, lupus, and rheumatoid arthritis (RA) may be detected in serum, providing a more straightforward diagnostic method and allowing for regular monitoring of disease activity. Neurofilament light chain (NfL), a blood-based marker, correlates similarly with neuronal damage in AE, providing information on the severity and course of the disease.
• Advanced Multi-Omics and Imaging
To facilitate early identification before severe symptoms appear, quantitative MRI and metabolomic/proteomic profiling can detect minor changes in the brain or metabolic abnormalities in AE. AI-powered analysis of clinical, genetic, and imaging data identifies patterns that humans cannot see, making it easier to distinguish between overlapping diseases, such as lupus and rheumatoid arthritis (RA).

End-Users
• Hospitals
• Diagnostics Centers
• Others

Market Trends for Autoimmune Disease Diagnostics in Asia Pacific
Due in large part to the rising prevalence of autoimmune disorders and the increased understanding of how to diagnose them, the Asia Pacific autoimmune disease diagnostics market is anticipated to grow significantly over the forecast period. Furthermore, inflammatory, autoimmune, and pulmonary conditions, such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease, are on the rise across Asia Pacific, according to a June 2022 study from Janssen, a part of Johnson & Johnson Pte. Ltd. In addition, the region already has the highest rates of systemic lupus erythematosus (SLE) in China and Southeast Asia, as well as the most significant burden of chronic obstructive pulmonary disease (COPD) worldwide. In the coming years, the Asia Pacific region's diagnostic demand is expected to rise significantly due to these alarming developments.
Over the projected period, the Japanese market for autoimmune disease diagnostics is expected to expand. According to a September 2024 Al Jazeera story, Japan's elderly population has reached a record 36.25 million, accounting for 29.3% of the country's overall population-the highest percentage in the world. The need for autoimmune disease diagnostics has grown as a result of this demographic trend, as older people are more likely to have autoimmune illnesses such as rheumatoid arthritis, systemic lupus erythematosus, and thyroid problems. As Japan's population ages due to low birth rates and rising life expectancy, this trend is expected to continue. Consequently, it is anticipated that Japan's need for autoimmune disease diagnostic services will grow over the next several years.

Regional Analysis
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey
Asia Pacific
• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand
Latin America
• Brazil
• Mexico
• Argentina
Middle East & Africa
• Saudi Arabia
• UAE
• South Africa

Recent Developments
The Benaroya Research Institute is launching a novel approach to early detection of autoimmune illnesses in February 2025. An autoantibody test is a unique blood test that is being added to routine examinations at the doctor's office. Before any symptoms appear, this test can help detect conditions such as rheumatoid arthritis and type 1 diabetes. Doctors can treat these illnesses more quickly and maybe prevent major issues if they are discovered early. Pilot testing is now in progress.
The Aurora, Colorado-based biotechnology startup RheumaGen obtained $15 million in Series A funding in January 2025, with SPRIM Global Investments and William Taylor Nominees serving as co-leads. The money will go toward RG0401's Phase I trial, a gene-editing medication that targets treatment-resistant rheumatoid arthritis by altering HLA genes to stop autoimmune reactions. The company's goal is to provide one-time, curative medicines for autoimmune conditions, including type 1 diabetes and multiple sclerosis.

Company Analysis:
• Abbott Laboratories
• Bio-Rad Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Bio Merieux SA
• Myriad Genetics, Inc.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

New Publish Reports
Human Papilloma Virus (HPV) Testing Market: https://www.renub.com/human-papilloma-virus-testing-market-p.php
North America Autoimmune Disease Diagnostics Market: https://www.renub.com/north-america-autoimmune-disease-diagnostics-market-p.php
Human Microbiome Market: https://www.renub.com/human-microbiome-market-p.php

Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com

About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

This release was published on openPR.